- Tumors1000+
- Pathology711
- Pathologic Processes696
- Cancer655
- Nervous System Diseases568
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathology711
- Pathologic Processes696
- Cancer655
- Nervous System Diseases568
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- EGFR negative
- PD-L1 negative
- EGFR positive
- PR positive
- ALK negative
- ER negative
- PR negative
- KRAS positive
- BRAF positive
- CD20 positive
- BRCA1 positive
- ALK positive
- BRAF negative
- BRCA2 positive
- ROS1 negative
- p16 positive
- MET positive
- MYC positive
- PIK3CA positive
- HLA positive
- RET positive
- p16 negative
- HR positive
- ROS1 positive
- BCL2 positive
- HLA-A positive
- PALB2 positive
- BCL6 positive
- IDH negative
- MET negative
- TP53 positive
- BCR-ABL1 positive
- Ex19del positive
- HBsAg positive
- IDH positive
- L858R positive
- RET negative
- TP53 negative
- dMMR positive
- Anti-dsDNA positive
- BRCA1 negative
- CCND1 positive
- CD19 positive
- CD5 positive
- HLA negative
- HLA-A negative
- HPV negative
- NRAS positive
- TTR positive
- ABCA4 positive
- ANA positive
- BRCA positive
- BRCA2 negative
- CFTR positive
- CLDN18.2 positive
- FGFR2 positive
- KRAS negative
- MDM2 positive
- MSI-H positive
- MSS positive
- NTRK negative
- NTRK positive
- PTEN positive
- RAS positive
- RB1 negative
- RB1 positive
- T790M positive
- TROP2 negative
- TROP2 positive
- ctDNA positive
- APP positive
- C5 positive
- CD23 positive
- COL7A1 positive
- EBV positive
- FLT3 negative
- FLT3 positive
- FMR1 positive
- HPV positive
- MGMT negative
- MMR positive
- NF1 positive
- PSEN1 positive
- PSEN2 positive
- Philadelphia Chromosome positive
- RAS negative
- RF positive
- RHO positive
- pMMR positive
- t(11;14) positive
- β-thalassemia positive
- 11q negative
- 11q positive
- AKT negative
- ALPL positive
- ATM positive
- Aβ1-42 positive
- CD20 negative
- CDK4 positive
- COL1A1 positive
- COL1A2 positive
- DLL3 positive
- DMD positive
- Del(17p) negative
- ER/PR positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GBA positive
- GLA positive
- GRN positive
- HBB positive
- HBV DNA negative
- HEXA positive
- HEXB positive
- HPV16 positive
- HRAS positive
- HRD positive
- HbE positive
- HbSS positive
- IGHV negative
- IGHV positive
- JAK2 positive
- KIT positive
- L861Q positive
- MGMT positive
- MLH1 positive
- MMR negative
- MSH2 positive
- MSH6 positive
- MSI-H negative
- MYC negative
- NF2 positive
- NRAS negative
- PDE6A positive
- PDE6B positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PMM2 positive
- PMS2 positive
- PTCH1 positive
- PTEN negative
- Philadelphia chromosome negative
- PiZZ positive
- RAF positive
- S768I positive
- SMN1 positive
- SPINK5 positive
- TTR negative
- anti-AChR positive
- anti-MuSK positive
- anti-PLA2R positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Sm positive
- anti-Smith positive
- dMMR negative
- kappa light chain positive
- lambda light chain positive
- other sickle cell syndrome variants positive
- p53 positive
- 11q del negative
- 11q del positive
- 12 negative
- 12 positive
- 13q del negative
- 13q negative
- 13q positive
- 16p11.2 deletion positive
- 17p del positive
- 17p negative
- 17p positive
- 17p13 deletion negative
- 19q negative
- 19q positive
- 1p negative
- 1p positive
- 1p/19q co-deletion positive
- 1p/19q loss positive
- 1p36 deletion positive
- 46 XX karyotype positive
- 5q SMA positive
- 5q-autosomal recessive SMA positive
- AAVrh74 antibody titers negative
- ABCD1 positive
- ABL-class fusion positive
- ABL-class fusions positive
- ABO negative
- ABO positive
- ACVR1 positive
- AChR positive
- AChR-Ab positive
- ADAMTS-13 negative
- ADAMTS-13 positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
- Anti-HER2 Therapy
- Anti-Seizure Medications (up to 2 types)
- Any Treatment for Pancreatic Cancer
- At least one prior tumor-directed therapy
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
3752 trials
1
2
3
…50